Clinical trials: ITP, open to volunteers
Immune Thrombocytopenia (ITP)
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly…
- Trial name
- NCT07065968
- Testing
- Teriflunomide, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
- Trial name
- NCT06941129
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
The goal of this observational study is to characterize the diagnostic and therapeutic management of autoimmune cytopenias including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune…
- Conditions
- Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia
- Trial name
- AIHA ITP CIN (NCT05931718)
- Testing
- cytokine essays, NGS, Fecal microbiome
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Immune Thrombocytopenia
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT07064889
- Testing
- Dexamethasone, Upadacitinib
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University People's Hospital
Chronic Primary Immune Thrombocytopenia (ITP)
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
- Trial name
- ITP (NCT07059000)
- Testing
- Kedrion IVIG 10%
- Where
- 28 sites in United States, Czechia and 6 more
- Volunteers
- 40 people
- Sponsor
- Kedrion S.p.A.
ITP - Immune Thrombocytopenia
Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and…
- Trial name
- Ava dosing (NCT07133659)
- Testing
- Avatrombopag 20 mg Oral Tablet
- Where
- Iraq
- Volunteers
- 25 people
- Sponsor
- Al-Mustansiriyah University
Immune Thrombocytopenia
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
- Trial name
- NCT07104565
- Testing
- INCA000585
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 56 people
- Sponsor
- Incyte Corporation
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one…
- Trial name
- NCT06168851
- Testing
- Anti-CD38 antibody Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenic Purpura, Coronary Artery Disease
Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization
This study employs a dual-cohort design to develop and validate a prognostic model for Major Adverse Cardiovascular Events (MACE) following revascularization in immune thrombocytopenia (ITP) patients with Coronary Artery Disease…
- Trial name
- ITP with CAD (NCT07426107)
- Volunteers
- 600 people
- Sponsor
- Xiao Hui Zhang
Immune Thrombocytopenia With Positive ANA Antibodies
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
The goal of this clinical trial is to learn if hydroxychloroquine (HCQ) plus thrombopoietin receptor agonists (TPO-RA) works to treat primary immune thrombocytopenia with positive anti-nuclear antibodies in adults.
- Trial name
- NCT06479291
- Testing
- Hydroxychloroquine Oral Tablet, Eltrombopag
- Where
- 7 sites in China, Hong Kong and 1 more
- Volunteers
- 126 people
- Sponsor
- Yunfeng Cheng
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
Safety Study of CC312 in Autoimmune Disease Patients
This study is an open-label, multiple-dose escalation, Investigator-Initiated Trial (IIT) clinical trial designed to evaluate the safety and tolerability of CC312 in adult patients with relapsed and refractory autoimmune…
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA)
- Trial name
- NCT06888960
- Testing
- CC312
- Where
- China
- Volunteers
- 18 people
- Sponsor
- CytoCares Inc
Immune Thrombocytopenic Purpura ( ITP ), Systemic Lupus Erythematosus (SLE)
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity…
- Trial name
- PRELUDE (NCT07680010)
- Testing
- Blood sampling baseline and M3, Monitoring for SLE, Procedure/Surgery: Blood sampling baseline and M3 then each 6 months until 48 months
- Where
- 2 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
ITP - Immune Thrombocytopenia
Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia
This study is an open label, randomized controlled, multicenter clinical trial aimed at comparing the efficacy and safety of the combination of atorvastatin and all trans retinoic acid with atorvastatin alone in the treatment of…
- Trial name
- NCT07278908
- Testing
- Avatrombopag+All trans retinoic acid, Avatrombopag
- Volunteers
- 248 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia (ITP)
rhTPO Dose Escalation vs Eltrombopag Switch in ITP
This study is a prospective, multicenter, randomized controlled study, planning to enroll 110 ITP patients who failed to respond to conventional-dose rhTPO (300 IU/kg/d) after 14 days of treatment (PLT < 30×10⁹/L).
- Trial name
- NCT07476846
- Testing
- Recombinant Human Thrombopoietin（rhTPO）, Eltrombopag PfOS
- Volunteers
- 112 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia, Treatment
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of elderly patients with primary immune thrombocytopenia in patients who have failed multiple treatment.
- Trial name
- NCT07063199
- Testing
- Daratumumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Persistent Immune Thrombocytopenia
Management of Children With Persistent ITP, A Novel Approach
The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP).
- Trial name
- LMICs (NCT07068126)
- Testing
- Mini-Pool IVIG
- Where
- 3 sites in Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Immune Thrombocytopenic Purpura (ITP)
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06948318
- Testing
- Mezagitamab
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Takeda
Immune Thrombocytopenia
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a…
- Trial name
- COGFIT (NCT06817395)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Immune Thrombocytopenia, Treatment
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.
- Trial name
- NCT06094881
- Testing
- Obinutuzumab Injection [Gazyva]
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Immune Thrombocytopenia
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT07017725
- Testing
- CID-103
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- CASI pharmaceuticals, Inc.